Related Experiment Video
Updated: Mar 14, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Demethylating Agents in the Treatment of Cancer
Paul M Howell1, Zixing Liu2, Hung T Khong3
1University of South Alabama, Mitchell Cancer Institute/1660 Springhill Ave., Mobile, AL 36604, USA. paulhowell@usouthal.edu.
Abstract:
Gene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy.
Insights
DNA methylation inhibitors, azacitidine and decitabine, are FDA-approved for myelodysplastic syndromes (MDS). This review covers their clinical data, benefits, toxicities, and use in solid tumors.
Area of Science:
- Oncology
- Epigenetics
Background:
- Aberrant DNA methylation silences genes, promoting tumorigenesis.
- DNA demethylating agents reactivate silenced genes in malignancies.
Approach:
- Review of clinical data for azacitidine and decitabine.
- Summary of clinical trials in myelodysplastic syndromes (MDS) and solid tumors.
- Discussion of clinical benefits, toxicities, and limitations.
Key Points:
- Azacitidine and decitabine are FDA-approved, standard-of-care treatments for MDS.
- These demethylating agents have been investigated for solid tumor therapy.
- Clinical benefits and toxicities are crucial considerations for their use.
Conclusions:
- Azacitidine and decitabine show efficacy in MDS and are explored in solid tumors.
- Understanding their limitations is key for optimizing cancer therapy.
- Further research may refine the application of these epigenetic drugs.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Treatment Resistant Cancers
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

